You Might Also Like
Also By This Author
- AbbVie Inc. News release: Upadacitinib meets all primary and ranked secondary endpoints including superiority versus adalimumab in Phase 3 study in rheumatoid arthritis. 2018 Apr 9.
Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.
Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.
Browse and search abstracts from the ACR/ARP Annual Meetings going back to 2012.